Key Morningstar Metrics for JPMorgan Global Select Equity Active ETF JGLO
- : Global EquityMorningstar Category
- : GoldMorningstar Medalist Rating
- : N/AMorningstar Rating
- MER: 0.53%
JPM Global Select is a standout option in the large-cap blend Morningstar Category and earns a High rating on both People and Process Pillars.
The strategy is led by Helge Skibeli, a JPMorgan veteran of nearly four decades, supported by comanager Christian Pecher. Skibeli has held senior research leadership roles across Asian, US, and global equities, making fundamental research the backbone of his career. His long tenure and proven ability to integrate research insights are key strengths here.
The portfolio management team expanded on June 30, 2026, with the appointments of Sam Witherow and Craig Morgan. Neither addition is surprising. Witherow, a 16-year firm veteran, already runs other global-focused strategies alongside Skibeli, and the two have a well-established working relationship. He spent his first eight years as an analyst before moving into global portfolio management, and his experience and complementary perspective add depth to the team.
Morgan brings more than a decade at J.P. Morgan and has managed several institutional mandates within the broader JPM Global Select strategy. His formal appointment here simply recognizes the role he was already playing.
Crucially, the portfolio managers are backed by J.P. Morgan’s deep fundamental analyst resources, one of the industry’s deepest and most experienced teams. Around 80 sector specialists each cover 20-35 companies, on average, bringing 17 years of industry experience and 13 years at the firm.
The strategy employs a disciplined, bottom-up stock-picking process supported by this extensive global research platform. Analysts covering 2,500+ companies classify stocks as premium, quality, standard, or challenged and assign five-year expected return targets to guide portfolio construction.
The managers primarily focus on premium and quality names, maintaining a valuation-conscious, conviction-driven approach in a focused portfolio of 65-95 holdings, with modest flexibility at the country or sector level and typically high turnover (50%–100%). The portfolio favors financially healthy, large- and mega-cap companies, with minimal small-cap exposure.
Under Skibeli’s management since December 2015, the strategy has delivered strong results. The C Acc Clean share class has returned an annualized 12.62% through July 2026, outpacing both the category average (9.45%) and the MSCI World Index (12.50%, in US dollars). Returns have exhibited somewhat higher volatility, but this has generally been rewarded with superior risk-adjusted outcomes versus peers.
Performance over 2025 was tough on a relative basis, with the fund underperforming its category and index by 6.7% and 7.9%, respectively. Weak stock selection and an underweight to momentum were the main drivers. More broadly, analyst research signals across the J.P. Morgan platform have come under pressure, as their grounding in long-term fundamentals has been overshadowed by the market’s emphasis on short-term momentum. These dynamics have persisted into 2026, though we still see merit in the approach given its long-term track record.
JPMorgan Global Select Equity Active ETF: Performance Highlights
Under Helge Skibeli’s management since December 2015, the strategy has delivered strong results. The C Acc Clean share class has returned an annualized 12.62% through July 2026, outpacing both the category average (9.45%) and the MSCI World index (12.50%, in US dollars). Returns have exhibited somewhat higher volatility, but this has generally been rewarded with superior risk-adjusted outcomes versus peers.
Stock selection has been the key driver of outperformance, and we would expect this core approach to outperform over a full market cycle. The emphasis on high-quality, durable businesses has provided some resilience during market stress, notably in 2022 when the fund declined 14.8% versus losses of 19.5% for peers and 18.1% for the index. Healthcare was a relatively bright spot that year, with overweight positions in AbbVie, Bristol-Myers, and Boston Scientific adding value.
The strategy rebounded sharply in 2023, gaining 27.4% and ranking in the fifth percentile of the category. Outperformance was primarily driven by technology names, including Microsoft and Uber, as well as overweight positions in Amazon.com and Meta Platforms.
Performance remained strong in 2024, with a 16.2% gain that exceeded the category average by 3.9%, though it lagged the MSCI World index’s 18.7% return. Technology again was the largest contributor, with positions in Nvidia, TSMC, and Apple boosting results.
Performance over 2025 was tough on a relative basis, with the fund underperforming its category and index by 6.7% and 7.9%, respectively. Weak stock selection and an underweighting in momentum were the main drivers. More broadly, analyst research signals across the J.P. Morgan platform have come under pressure, as their grounding in long-term fundamentals has been overshadowed by the market’s emphasis on short-term momentum. These dynamics have persisted into 2026, though we still see merit in the approach given its long-term record.
